273 related articles for article (PubMed ID: 15084248)
21. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
22. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
Borgquist S; Jögi A; Pontén F; Rydén L; Brennan DJ; Jirström K
Breast Cancer Res; 2008; 10(5):R79. PubMed ID: 18808688
[TBL] [Abstract][Full Text] [Related]
24. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
25. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis.
Révillion F; Lhotellier V; Hornez L; Bonneterre J; Peyrat JP
Ann Oncol; 2008 Jan; 19(1):73-80. PubMed ID: 17962208
[TBL] [Abstract][Full Text] [Related]
26. Early (<10 mm) HER2-Positive Invasive Breast Carcinomas are Associated with Extensive Diffuse High-Grade DCIS: Implications for Preoperative Mapping, Extent of Surgical Intervention, and Disease-Free Survival.
Tot T
Ann Surg Oncol; 2015 Aug; 22(8):2532-9. PubMed ID: 25582746
[TBL] [Abstract][Full Text] [Related]
27. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
28. Role of HER2 in wound-induced breast carcinoma proliferation.
Tagliabue E; Agresti R; Carcangiu ML; Ghirelli C; Morelli D; Campiglio M; Martel M; Giovanazzi R; Greco M; Balsari A; Ménard S
Lancet; 2003 Aug; 362(9383):527-33. PubMed ID: 12932384
[TBL] [Abstract][Full Text] [Related]
29. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer in very young women.
Liukkonen S; Leidenius M; Saarto T; Sjöström-Mattson J
Eur J Surg Oncol; 2011 Dec; 37(12):1030-7. PubMed ID: 21937191
[TBL] [Abstract][Full Text] [Related]
31. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor (EGFR) as a prognostic marker: an immunohistochemical study on 315 consecutive breast carcinoma patients.
Aziz SA; Pervez S; Khan S; Kayani N; Rahbar MH
J Pak Med Assoc; 2002 Mar; 52(3):104-10. PubMed ID: 12071064
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
Francis G; Beadle G; Thomas S; Mengersen K; Stein S
Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
[TBL] [Abstract][Full Text] [Related]
34. Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.
Jirström K; Rydén L; Anagnostaki L; Nordenskjöld B; Stål O; Thorstenson S; Chebil G; Jönsson PE; Fernö M; Landberg G
J Clin Pathol; 2005 Nov; 58(11):1135-42. PubMed ID: 16254100
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of a positive axillary lymph node fine-needle aspirate in patients with invasive breast carcinoma.
Chang MC; Escallon JM; Colgan TJ
Cancer Cytopathol; 2014 Feb; 122(2):138-44. PubMed ID: 24106096
[TBL] [Abstract][Full Text] [Related]
36. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis.
Fujiwara S; Ibusuki M; Yamamoto S; Yamamoto Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):472-81. PubMed ID: 23100016
[TBL] [Abstract][Full Text] [Related]
37. HER-2/neu expression in primary and metastatic breast cancer.
Lower EE; Glass E; Blau R; Harman S
Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
[TBL] [Abstract][Full Text] [Related]
38. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.
Ferrero-Poüs M; Hacène K; Bouchet C; Le Doussal V; Tubiana-Hulin M; Spyratos F
Clin Cancer Res; 2000 Dec; 6(12):4745-54. PubMed ID: 11156229
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
[TBL] [Abstract][Full Text] [Related]
40. Combined overexpression of c-erbB-2 protein and epidermal growth factor receptor (EGF-R) could be predictive of early and long-term outcome in human breast cancer: a pilot study.
Delarue JC; Terrier P; Terrier-Lacombe MJ; Mouriesse H; Gotteland M; May-Levin F
Bull Cancer; 1994 Dec; 81(12):1067-77. PubMed ID: 7742595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
